Bluejay Diagnostics, Inc. 8K

Bluejay Diagnostics reported Q2 2026 results, completed pivotal SYMON-II trial enrollment, advanced toward an FDA 510(k) submission and commercialization for its Symphony IL-6 test, and strengthened liquidity via a June 2026 financing.

Bluejay Diagnostics, Inc. filed a Form 8-K to furnish a press release announcing its Q2 2026 financial results and operational progress, highlighting completion of targeted enrollment of 750 patients in its SYMON-II pivotal clinical validation study for the Symphony IL-6 test, advancement toward an FDA 510(k) submission and commercialization including signing a U.S. manufacturing contract to mitigate supply-chain risk, and a strengthened balance sheet with approximately $9.6 million in cash at June 30, 2026 following a June 2026 private placement that extended the company’s estimated cash runway through the second quarter of 2027.

Filing Facts

CIK

1704287

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-088701

Alert Tier

6